Stocktoria
Inmune Bio, Inc. INMB
Nasdaq · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2019-02-04
Inmune Bio, Inc. statistics & valuation
Market cap$37.8M
P / B1.6×
Net margin-91866.0%
Return on equity-195.3%
FCF margin-47248.0%
Return on capital-198%
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else from the latest financial reports.
Profitability & efficiency
Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Operating margin | -94766.0% | -304535.7% | -19187.7% | -6938.8% | -16106.6% | -111163.6% | — | — | — |
| Net margin | -91866.0% | -300585.7% | -19360.0% | -7299.2% | -16762.4% | -109990.9% | — | — | — |
| FCF margin | -47248.0% | — | — | — | — | — | — | — | — |
| Return on assets | -142.0% | -106.4% | -52.6% | -33.4% | -30.4% | -29.8% | -31.4% | -71.6% | -4.5% |
| Return on equity | -195.3% | -131.1% | -80.4% | -45.4% | -37.8% | -31.2% | -32.5% | -75.2% | -4.6% |
| Debt / equity | — | 0.47× | — | 0.25× | 0.19× | — | — | — | — |
| Current ratio | 3.55 | 3.14 | 2.16 | 5.92 | 18.95 | 13.51 | 11.09 | 1.03 | — |
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.